dalteparin has been researched along with Coxarthrosis in 4 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our experience with rivaroxaban in elective hip and knee arthroplasty showed no significant difference in the incidence of VTE or major bleeding." | 3.79 | Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing. ( Jeer, P; Rose, B; Saran, D; Shrivastava, R; Sindali, K; Soueid, H, 2013) |
| " In the patients of both groups the product dabigatran etexilate in the standard dosage (220 mg/day) was used for specific prevention." | 1.43 | [Substantiation of the system of thrombus formation prevention in treatment of patients with hip joint pathology against the background of arterial insufficiency of the lower extremities]. ( Akhtyamov, IF; Shigaev, ES; Ziatdinov, BG, 2016) |
| " LMWH allows for consistent dosing in postoperative patients without the need for laboratory monitoring." | 1.30 | Intrahepatic hemorrhage after use of low-molecular-weight heparin for total hip arthroplasty. ( Houde, JP; Steinberg, G, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sindali, K | 1 |
| Rose, B | 1 |
| Soueid, H | 1 |
| Jeer, P | 1 |
| Saran, D | 1 |
| Shrivastava, R | 1 |
| Akhtyamov, IF | 1 |
| Ziatdinov, BG | 1 |
| Shigaev, ES | 1 |
| Houde, JP | 1 |
| Steinberg, G | 1 |
| Borgen, PO | 1 |
| Dahl, OE | 1 |
| Reikerås, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomized, Double Blind Study to Evaluate Safety and Effect With Pre Versus Postoperative Start of Thromboprophylaxis With Dalteparin[NCT01714297] | Phase 4 | 80 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for dalteparin and Coxarthrosis
| Article | Year |
|---|---|
Blood loss in cemented THA is not reduced with postoperative versus preoperative start of thromboprophylaxis.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Biomarkers; Blood Loss, Surgical; Blood Tra | 2012 |
3 other studies available for dalteparin and Coxarthrosis
| Article | Year |
|---|---|
Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Chemopreventi | 2013 |
[Substantiation of the system of thrombus formation prevention in treatment of patients with hip joint pathology against the background of arterial insufficiency of the lower extremities].
Topics: Aged; Anticoagulants; Arterial Occlusive Diseases; Arthroplasty, Replacement, Hip; Blood Coagulation | 2016 |
Intrahepatic hemorrhage after use of low-molecular-weight heparin for total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Chemical and Drug Induced Liver Injury; Eno | 1999 |